Upgrade to SI Premium - Free Trial

The Chemours Company Reports Third Quarter 2016 Results; Significant Earnings and Margins Increases Driven by Progress on Transformation Plan and Improved Market Conditions

November 6, 2016 4:30 PM

WILMINGTON, Del., Nov. 6, 2016 /PRNewswire/ --

Third Quarter 2016 Highlights

  • Net Sales of $1.4 billion
  • Net Income of $204 million, or $1.11 per diluted share, including gain on asset sales of $169 million, impairment charges of $46 million, interest expense of $51 million and restructuring costs of $14 million
  • Adjusted EBITDA of $268 million
  • Adjusted Net Income of $112 million, or $0.61 per diluted share

Other Highlights

  • Continued progress on all transformation plan objectives, including cost reductions, growth initiatives and portfolio rationalization
  • Improved cash from operating activities by ~$440 million year-to-date
  • Retired $315 million of long term debt through October 31, 2016
  • Generated ~$685 million in gross proceeds from Chemical Solutions divestitures
  • Increased full-year Adjusted EBITDA outlook to be between $740 and $775 million based on a net income range of approximately $265 to $290 million

The Chemours Company (Chemours) (NYSE: CC), a global chemistry company with leading market positions in titanium technologies, fluoroproducts and chemical solutions, today announced financial results for the third quarter 2016.

Chemours President and CEO Mark Vergnano said, "We continue to make excellent progress on all aspects of our transformation plan, realizing an incremental $60 million of cost savings during the quarter. We are benefiting from the OpteonTM refrigerant ramp up and the expansion of our low-cost TiO2 capacity at Altamira, while at the same time, delivering our planned cost reductions." He continued, "We successfully completed the Chemical Solutions portfolio review during the quarter, generating substantial proceeds. And, in the quarter, our Titanium Technologies business benefited from more favorable market conditions, while the fluoropolymers market remained challenged. Transformation initiatives are pervasive throughout the company and our results speak for themselves."

Third quarter net sales were $1.4 billion, a decrease of 6 percent from $1.5 billion in the prior-year quarter, primarily due to the impact of divestitures. Third quarter net income was $204 million, or $1.11 per diluted share, versus net loss of $29 million, or ($0.16) per diluted share in the prior-year quarter. Adjusted EBITDA for the third quarter was $268 million versus $169 million in the prior-year quarter. Benefits from cost reductions, improved average prices in Titanium Technologies and improved profitability in Fluoroproducts was partially offset by the loss of Adjusted EBITDA from the asset sales within Chemical Solutions.

Sequentially, sales increased 1 percent to $1.4 billion in the third quarter. Third quarter net income was $222 million higher, or $1.21 per diluted share, versus the second quarter net loss of $18 million or ($0.10) per diluted share. The sales improvement was largely driven by higher seasonal volumes in Titanium Technologies and Fluoroproducts supplemented by higher TiO2 pricing. Third quarter Adjusted EBITDA increased $81 million from $187 million in the second quarter of 2016. Improved pricing in Titanium Technologies and OpteonTM refrigerant growth in Fluoroproducts were the primary drivers of the improved sequential performance, which were partially offset by unfavorable Corporate and Other expenses.

Titanium TechnologiesIn the third quarter, Titanium Technologies segment sales were $625 million, a 1 percent increase versus the prior-year quarter. Improved year-over-year global average TiO2 pricing increased sales 2 percent which was partially offset by minimal currency headwinds. Year-over-year, TiO2 volume was higher in all regions outside of China. Segment Adjusted EBITDA was $144 million, an 80 percent increase over the prior-year quarter. The increase in Adjusted EBITDA was primarily due to the benefits of price increases, transformation plan cost savings, and operational efficiencies.

Sequentially, versus the second quarter of 2016, sales increased 5 percent and Adjusted EBITDA increased $33 million, or 30 percent. The increase in sales was due to slightly stronger volumes and a higher global average price increase of approximately 3 percent. A volume increase of 2 percent was the result of stronger demand primarily in Asia and Latin America. Higher Adjusted EBITDA was driven by the benefits of global average price increases, stronger volumes and better utilization resulting in lower costs.

FluoroproductsFluoroproducts segment sales in the third quarter were $591 million, an increase of 3 percent versus the prior-year quarter. A substantial increase in demand for Opteon™ refrigerants was mostly offset by government-imposed volume reductions of base refrigerants as well as competitive pricing pressure within fluoropolymers. Segment Adjusted EBITDA was $143 million, a 57 percent improvement versus the prior-year quarter. Increased contributions from Opteon™ refrigerants and transformation cost reductions were partially offset by unfavorable pricing and mix within our fluoropolymers product lines.

Sequentially, versus the second quarter of 2016, sales and Adjusted EBITDA increased 3 percent and 36 percent, respectively. The Opteon™ refrigerants ramp up and strong demand for certain fluoropolymers products more than offset regulatory-driven lower demand in base refrigerant sales. In addition to Opteon™ refrigerant growth, the increase in Adjusted EBITDA was primarily attributed to cost reductions.

Chemical SolutionsIn the third quarter, Chemical Solutions segment sales were $182 million, a 38 percent decline versus the prior-year quarter. Lower sales were driven by the divestitures of the Clean and Disinfect business, Sulfur Products and Beaumont Aniline facility, as well as reduced average prices based on contractual pass-through terms. Segment Adjusted EBITDA was $9 million, $1 million above the prior-year quarter, reflecting lower operating costs partially offset by the impacts of the divestitures.

Sequentially, sales decreased 15 percent versus the second quarter of 2016, while Adjusted EBITDA was $2 million lower driven primarily by portfolio changes completed in the current quarter.

In the third quarter, we completed the sales of Sulfur Products and the Clean and Disinfect business to Veolia and LANXESS, respectively, for combined proceeds of approximately $544 million. Also, consistent with the company's plan to streamline the portfolio and deliver cost savings in 2017, the company ceased production at the Niagara Reactive Metals facility at the end of September.

Corporate and OtherCorporate and Other represented a negative $28 million of Adjusted EBITDA, an increase of $18 million versus the prior-year quarter. Higher expenses were primarily related to performance-related compensation adjustments and other miscellaneous expenses in the quarter. Versus the second quarter of 2016, Corporate and Other expenses declined $12 million largely due to timing of expenses.

The company realized a cash tax rate of approximately 16 percent in the quarter. For the full year 2016, the company expects its cash tax rate to be in the low-twenties on a percentage basis, taking into consideration the company's anticipated geographic mix of earnings and implications of all divestitures during the year.

LiquidityAs of September 30, 2016, gross consolidated debt was $3.8 billion. Debt, net of cash, was $2.8 billion. In the quarter, the company retired approximately $115 million of its bonds. Cash balances were $957 million at September 30, 2016. In October 2016, the company retired an additional $107 million of its bonds, resulting in over $315 million of total long term debt retired year-to-date. As a result, the company expects to save approximately $19 million annually from lower interest obligations.

Improved inventory management along with the start of seasonal working capital unwind drove strong progress in working capital results and led to free cash flow of $132 million, up $124 million versus the previous-year quarter. Year-to-date working capital1 performance and free cash flow improved by $448 million and $601 million, respectively, versus the prior-year.

Outlook"We remain disciplined and focused on executing our Five-Point Transformation Plan," Vergnano commented. "We expect the transformation plan improvements, along with a stronger price environment for TiO2 and increased OpteonTM refrigerants adoption to continue to enhance earnings, despite loss of earnings from divestitures, base refrigerant sales timing and unfavorable Fluoropolymers mix. We now expect full-year 2016 Adjusted EBITDA to be between $740 million and $775 million. We are pleased with the progress we have made year-to-date, and believe we are in a stronger position as we move forward."

Conference CallAs previously announced, Chemours will hold a conference call and webcast on Monday, November 7, 2016 at 8:30 AM EST. The webcast and additional presentation materials can be accessed by visiting the Events & Presentations page of Chemours' investor website, investors.chemours.com. A webcast replay of the conference call will be available on the Chemours' investor website.

About The Chemours CompanyThe Chemours Company (NYSE: CC) helps create a colorful, capable and cleaner world through the power of chemistry. Chemours is a global leader in titanium technologies, fluoroproducts and chemical solutions, providing its customers with solutions in a wide range of industries with market-defining products, application expertise and chemistry-based innovations. Chemours ingredients are found in plastics and coatings, refrigeration and air conditioning, mining and oil refining operations and general industrial manufacturing. Our flagship products include prominent brands such as Teflon™, Ti-Pure™, Krytox™, Viton™, Opteon™ and Nafion™. Chemours has approximately 8,000 employees across 25 manufacturing sites serving more than 5,000 customers in North America, Latin America, Asia-Pacific and Europe. Chemours is headquartered in Wilmington, Delaware and is listed on the NYSE under the symbol CC. For more information please visit chemours.com.

Non-GAAP Financial MeasuresWe prepare our financial statements in accordance with Generally Accepted Accounting Principles ("GAAP"). Within this press release, we make reference to Adjusted Net Income (Loss), Adjusted Diluted Income (Loss) per share and Adjusted EBITDA and Free Cash Flow, which are non-GAAP financial measures. Free Cash Flow is defined as Cash from Operations minus cash used for PP&E purchases. The company includes these non-GAAP financial measures because management believes they are useful to investors in that they provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making.

Management uses Adjusted Net Income (Loss), Adjusted Diluted Income (Loss) per share, Adjusted EBITDA and Free Cash Flow to evaluate the company's performance excluding the impact of certain non-cash charges and other special items which we expect to be infrequent in occurrence in order to have comparable financial results to analyze changes in our underlying business from quarter to quarter.

Accordingly, the company believes the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing the company's operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. This analysis, as well as the other information in this press release, should be read in conjunction with the company's financial statements and footnotes contained in the documents that the company files with the U.S. Securities and Exchange Commission. The non-GAAP financial measures used by the company in this press release may be different from the methods used by other companies. For more information on the non-GAAP financial measures, please refer to the attached schedules or the table, "Reconciliation of Non-GAAP Financial Measures to GAAP Financial Measures" and materials posted to the website at investors.chemours.com.

Forward-Looking StatementsThis press release contains forward-looking statements, which often may be identified by their use of words like "plans," "expects," "will," "believes," "intends," "estimates," "anticipates" or other words of similar meaning. These forward-looking statements address, among other things, our anticipated future operating and financial performance, business plans and prospects, transformation plans, resolution of environmental liabilities, litigation and other contingencies, plans to increase profitability, our ability to pay or the amount of any dividend, and target leverage that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. The matters discussed in these forward-looking statements also are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those projected, anticipated or implied in the forward-looking statements, as further described in our filings with the Securities and Exchange Commission, including our annual report on Form 10-K for the fiscal year ended December 31, 2015. Chemours undertakes no duty to update any forward-looking statements.

CONTACT:

MEDIA:Alvenia ScarboroughDirector, Brand Marketing and Corporate Communications+1.302.773.4507[email protected]

INVESTORS:Alisha BellezzaTreasurer and Director of Investor Relations+1.302.773.2263[email protected]

The Chemours Company Consolidated Statements of Operations (Unaudited) (Dollars in millions, except per share amounts)

Three months ended

Nine months ended

September 30,

September 30,

2016

2015

2016

2015

Net sales

$

1,398

$

1,486

$

4,078

$

4,357

Cost of goods sold

1,056

1,222

3,267

3,615

Gross profit

342

264

811

742

Selling, general and administrative expense

148

157

454

481

Research and development expense

19

18

60

68

Restructuring and asset related charges, net

60

184

145

245

Goodwill impairment

25

25

Total expenses

227

384

659

819

Equity in earnings of affiliates

9

7

17

18

Interest expense, net

(51)

(51)

(157)

(79)

Other income, net

161

57

250

71

Income (loss) before income taxes

234

(107)

262

(67)

Provision (benefit from) for income taxes

30

(78)

25

(63)

Net income (loss)

204

(29)

237

(4)

Less: Net income attributable to noncontrolling interests

Net income (loss) attributable to Chemours

$

204

$

(29)

$

237

$

(4)

Per share data

Basic earnings (loss) per share of common stock

$

1.12

$

(0.16)

$

1.31

$

(0.02)

Diluted earnings per share of common stock

$

1.11

$

(0.16)

$

1.30

$

(0.02)

Dividends per share of common stock

$

0.03

$

0.03

$

0.09

$

0.58

The Chemours Company Consolidated Balance Sheets (Dollars in millions, except per share amounts)

September 30, 2016

December 31, 2015

(Unaudited)

Assets

Current assets:

Cash and cash equivalents

$

957

$

366

Accounts and notes receivable - trade, net

881

859

Inventories

846

972

Prepaid expenses and other

73

104

Total current assets

2,757

2,301

Property, plant and equipment

8,218

9,015

Less: Accumulated depreciation

(5,393)

(5,838)

Net property, plant and equipment

2,825

3,177

Goodwill

153

166

Other intangible assets, net

18

10

Investments in affiliates

169

136

Other assets

367

508

Total assets

$

6,289

$

6,298

Liabilities and equity

Current liabilities:

Accounts payable

$

835

$

973

Short-term borrowings and current maturities of long-term debt

32

39

Other accrued liabilities

569

454

Total current liabilities

1,436

1,466

Long-term debt, net

3,713

3,915

Deferred income taxes

201

234

Other liabilities

558

553

Total liabilities

5,908

6,168

Commitments and contingent liabilities

Equity

Common stock (par value $0.01 per share; 810,000,000 shares authorized; 181,720,722 shares issued and outstanding as of September 30, 2016)

2

2

Additional paid in capital

781

775

Retained earnings (accumulated deficit)

117

(115)

Accumulated other comprehensive loss

(523)

(536)

Total Chemours stockholders' equity

377

126

Noncontrolling interests

4

4

Total equity

381

130

Total liabilities and equity

$

6,289

$

6,298

The Chemours Company Consolidated Statements of Cash Flows (Unaudited) (Dollars in millions)

Nine months ended

September 30,

2016

2015

Operating activities

Net income (loss)

$

237

$

(4)

Adjustments to reconcile net income (loss) to cash used for operating activities:

Depreciation and amortization

212

201

Amortization of debt issuance costs and discount

15

5

Gain on sale of assets and business

(258)

Equity in earnings of affiliates

(17)

(18)

Deferred tax benefits

(29)

(86)

Asset related charges

109

191

Other operating charges and credits, net

33

17

(Increase) decrease in operating assets:

Accounts and notes receivable - trade, net

(63)

(250)

Inventories and other operating assets

113

(29)

Decrease in operating liabilities:

Accounts payable and other operating liabilities

(28)

(147)

Cash provided by (used for) operating activities

324

(120)

Investing activities

Purchases of property, plant and equipment

(235)

(392)

Purchase of Intangible Assets

Proceeds from sales of assets and business, net of cash transferred

707

8

Foreign exchange contract settlements

(1)

61

Investment in affiliates

(2)

(32)

Cash provided by (used for) investing activities

469

(355)

Financing activities

Proceeds from issuance of debt, net

3,490

Debt repayments

(212)

(6)

Deferred financing fees

(2)

(79)

Dividends paid

(16)

(100)

Cash provided at separation by DuPont

247

Net transfers to DuPont

(2,857)

Cash (used for) provided by financing activities

(230)

695

Effect of exchange rate changes on cash and cash equivalents

28

(5)

Increase in cash and cash equivalents

591

215

Cash and cash equivalents at beginning of period

366

Cash and cash equivalents at end of period

$

957

$

215

Non-cash investing activities:

Change in property, plant and equipment included in accounts payable

$

9

$

(42)

The Chemours Company Segment Financial and Operating Data (Unaudited) (Dollars in millions)

Segment Net Sales

Three months ended

Three months ended

Sequential

September 30,

Increase / (Decrease)

June 30,

Increase / (Decrease)

2016

2015

2016

Titanium Technologies

$

625

$

616

$

9

$

596

$

29

Fluoroproducts

591

575

16

573

18

Chemical Solutions

182

295

(113)

214

(32)

Net sales

$

1,398

$

1,486

$

(88)

$

1,383

$

15

Segment Adjusted EBITDA

Three months ended

Three months ended

Sequential

September 30,

Increase / (Decrease)

June 30,

Increase / (Decrease)

2016

2015

2016

Titanium Technologies

$

144

$

80

$

64

$

111

$

33

Fluoroproducts

143

91

52

105

38

Chemical Solutions

9

8

1

11

(2)

Corporate and Other

(28)

(10)

(18)

(40)

12

Total Adjusted EBITDA

$

268

$

169

$

99

$

187

$

81

Adjusted EBITDA Margin

19

%

11

%

14

%

Quarterly Change in Net Sales from September 30, 2015

September 30, 2016

Net Sales

Percentage Change vs 2015

Percentage change due to:

Local Price

Volume

Currency Effect

Portfolio / Other

Total Company

$

1,398

(6)%

(1)%

—%

—%

(5)%

Titanium Technologies

$

625

1%

1%

—%

—%

—%

Fluoroproducts

$

591

3%

(2)%

5%

—%

—%

Chemical Solutions

$

182

(38)%

(7)%

(5)%

—%

(26)%

Quarterly Change in Net Sales from June 30, 2016

September 30, 2016

Net Sales

Percentage Change vs June 30, 2016

Percentage change due to:

Local Price

Volume

Currency Effect

Portfolio / Other

Total Company

$

1,398

1%

1%

3%

—%

(3)%

Titanium Technologies

$

625

5%

3%

2%

—%

—%

Fluoroproducts

$

591

3%

—%

3%

—%

—%

Chemical Solutions

$

182

(15)%

(3)%

9%

—%

(21)%

The Chemours Company Segment Financial and Operating Data (Unaudited) (Dollars in millions)

Segment Net Sales

Nine months ended

September 30,

Increase / (Decrease)

2016

2015

Titanium Technologies

$

1,742

$

1,803

$

(61)

Fluoroproducts

1,695

1,715

(20)

Chemical Solutions

641

839

(198)

Net sales

$

4,078

$

4,357

$

(279)

Segment Adjusted EBITDA

Nine months ended

September 30,

Increase / (Decrease)

2016

2015

Titanium Technologies

$

309

$

264

$

45

Fluoroproducts

333

220

113

Chemical Solutions

30

13

17

Corporate and Other

(89)

(56)

(33)

Total Adjusted EBITDA

$

583

$

441

$

142

Adjusted EBITDA Margin

14

%

10

%

Year-to-date Change in Net Sales from September 30, 2015

2016

Net Sales

Percentage Change vs 2015

Percentage change due to:

Local Price

Volume

Currency Effect

Portfolio / Other

Total Company

$

4,078

(6)%

(4)%

1%

(1)%

(2)%

Titanium Technologies

$

1,742

(3)%

(6)%

3%

—%

—%

Fluoroproducts

$

1,695

(1)%

—%

1%

(2)%

—%

Chemical Solutions

$

641

(24)%

(8)%

(4)%

—%

(12)%

The Chemours Company Reconciliations of Non-GAAP Information (Unaudited)

GAAP Net Income (Loss) to Adjusted Net Income and Adjusted EBITDA Tabular Reconciliations (Dollars in millions)

Three months ended

Nine months ended

September 30,

June 30,

September 30,

2016

2015

2016

2016

2015

Net income (loss) attributable to Chemours

$

204

$

(29)

$

(18)

$

237

$

(4)

Non-operating pension and other postretirement employee benefit (income) costs

(5)

(10)

(7)

(19)

5

Exchange losses (gains)

17

(44)

14

37

(47)

Restructuring charges

14

139

9

41

200

Asset related charges1

46

70

63

109

70

(Gain) loss on sale of assets or business

(169)

1

(258)

Transaction costs2

2

12

18

Legal and other charges3

5

13

24

(Benefit from) provision for income taxes relating to reconciling items4

(2)

(53)

(38)

(16)

(82)

Adjusted Net Income

112

73

49

173

142

Net income attributable to noncontrolling interests

Interest expense, net

51

51

50

157

79

Depreciation and amortization

73

70

73

212

201

All remaining provision for (benefit from) income taxes4

32

(25)

15

41

19

Adjusted EBITDA

$

268

$

169

$

187

$

583

$

441

1

The three and nine months ended September 30, 2016 includes $46 million pre-tax asset impairment of our Pascagoula Aniline facility and other asset write-offs. The nine months ended September 30, 2016 also included $58 million pre-tax asset impairment in connection with the sale of the Sulfur business and other asset write-offs, which were recorded in the second quarter of 2016. The three and nine months ended September 30, 2015 includes $25 million of goodwill impairment and $45 asset impairment of the RMS facility. All of these charges are recorded in the Chemical Solutions segment.

2

Includes accounting, legal and bankers transaction fees incurred related to the Company's strategic initiatives, which includes pre-sale transaction costs incurred in connection with the sales of the C&D and Sulfur businesses.

3

Includes litigation settlements, water treatment accruals related to PFOA, and lease termination charges.

4

Total of provision for (benefit from) income taxes reconciles to the amount reported in the Interim Consolidated Statements of Operations for the three and nine months ended September 30, 2016 and 2015.

Adjusted Net Income diluted earnings per share is calculated using Adjusted Net Income divided by diluted weighted-average shares of common shares outstanding during each period, which includes unvested restricted shares. The table below shows a reconciliation of the numerator and denominator for basic and diluted earnings per share and adjusted earnings per share calculations for the periods indicated:

Three months ended

Nine months ended

September 30,

June 30,

September 30,

2016

2015

2016

2016

2015

Numerator:

Net income

$

204

$

(29)

$

(18)

$

237

$

(4)

Adjusted Net Income

$

112

$

73

$

49

$

173

$

142

Denominator:

Weighted-average number of common shares outstanding - Basic

181,596,161

180,968,049

181,477,672

181,452,194

180,968,049

Dilutive effect of the company's employee compensation plans 5

1,932,395

918,680

1,114,845

1,089,738

918,680

Weighted average number of common shares outstanding - Diluted

183,528,556

181,886,729

182,592,517

182,541,932

181,886,729

Earnings per share - basic

$

1.12

$

(0.16)

$

(0.10)

$

1.31

$

(0.02)

Earnings per share - diluted5

$

1.11

$

(0.16)

$

(0.10)

$

1.30

$

(0.02)

Adjusted earnings per share – basic

$

0.62

$

0.40

$

0.27

$

0.95

$

0.78

Adjusted earnings per share - diluted5

$

0.61

$

0.40

$

0.27

$

0.95

$

0.78

5

Diluted earnings (loss) per share is calculated using net income (loss) available to common shareholders divided by diluted weighted-average shares of common shares outstanding during each period, which includes unvested restricted shares. Diluted earnings per share considers the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential common shares would have an antidilutive effect.

The Chemours Company Reconciliations of Non-GAAP Information (Unaudited)

Estimated Income Before Income Taxes and Estimated Adjusted EBITDA Tabular Reconciliations (Dollars in millions)

2016 Full Year Estimate

(Dollars in millions)

Low

High

Net income attributable to Chemours

$

265

$

290

Non-operating pension and other postretirement employee benefit (income) costs

(25)

(20)

Exchange losses1

37

37

Restructuring charges

50

45

Asset related charges2

109

109

Gain on sale of assets or business2

(258)

(258)

Transaction costs, legal and other charges2

42

42

Provision for income taxes relating to reconciling items3

(20)

(20)

Adjusted pre-tax income

200

225

Net income attributable to noncontrolling interests

Interest expense, net

210

210

Depreciation and amortization

280

280

All remaining provision for income taxes3

50

60

Adjusted EBITDA

$

740

$

775

1

The amount represents the year-to-date net exchange losses incurred in the nine months ended September 30, 2016. Full year actual results could differ from the current estimate. and therefore could also change our estimated income before income taxes. Forecasting the remeasurement impact of foreign currency exchange fluctuation is not practical without unreasonable effort.

2

At this time, we cannot estimate additional impairment, gain on sale, transaction costs and legal and other charges. Therefore, the amounts included are the same as the actual amounts reported in the nine months period ended September 30, 2016.

3

Provision for (benefit from) income taxes were estimated based upon current geographical mix of earnings. Actual provision for (benefit from) income tax could defer from current estimate.

GAAP Cash Flow to Free Cash Flow Tabular Reconciliations

Three months ended

Nine months ended

September 30,

June 30,

September 30,

2016

2015

2016

2016

2015

Cash flow provided by (used for) operating activities

$

199

$

113

$

90

$

324

$

(120)

Cash flow used for purchases of property, plant and equipment

(67)

(105)

(79)

(235)

(392)

Free cash flows 4

$

132

$

8

$

11

$

89

$

(512)

4

Cash flows from operating activities for the nine months ended September 30, 2016 include the DuPont prepayments outstanding balance of approximately $93 million. Excluding the DuPont prepayment, free cash flows for the nine months ended September 30, 2016 would have been negative $4 million.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-chemours-company-reports-third-quarter-2016-results-significant-earnings-and-margins-increases-driven-by-progress-on-transformation-plan-and-improved-market-conditions-300358103.html

SOURCE The Chemours Company

Categories

Press Releases

Next Articles